CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study

Introduction. Melanoma is the most aggressive type of skin cancer, with poor prognosis in advanced stages. The incidence and mortality rates have increased in recent years. Single nucleotide polymorphisms p.R24P, p.M53I, p.G101W, p.V126D, and p.A148T in the CDKN2A (HGNC ID: 1787) gene have been asso...

Full description

Bibliographic Details
Main Authors: Jose D. Tovar-Parra, Luz D. Gutiérrez-Castañeda, Sebastián R. Gil-Quiñones, Jhon A. Nova, Leonardo Pulido
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2020/7458917
id doaj-16d2cda777384163b64f63e8a6fe7306
record_format Article
spelling doaj-16d2cda777384163b64f63e8a6fe73062020-11-25T04:00:17ZengHindawi LimitedBioMed Research International2314-61332314-61412020-01-01202010.1155/2020/74589177458917CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control StudyJose D. Tovar-Parra0Luz D. Gutiérrez-Castañeda1Sebastián R. Gil-Quiñones2Jhon A. Nova3Leonardo Pulido4Hospital Universitario-Centro Dermatológico Federico Lleras Acosta, E.S.E., DC, Bogotá, Colombia 111511, ColombiaHospital Universitario-Centro Dermatológico Federico Lleras Acosta, E.S.E., DC, Bogotá, Colombia 111511, ColombiaHospital Universitario-Centro Dermatológico Federico Lleras Acosta, E.S.E., DC, Bogotá, Colombia 111511, ColombiaHospital Universitario-Centro Dermatológico Federico Lleras Acosta, E.S.E., DC, Bogotá, Colombia 111511, ColombiaHospital Universitario-Centro Dermatológico Federico Lleras Acosta, E.S.E., DC, Bogotá, Colombia 111511, ColombiaIntroduction. Melanoma is the most aggressive type of skin cancer, with poor prognosis in advanced stages. The incidence and mortality rates have increased in recent years. Single nucleotide polymorphisms p.R24P, p.M53I, p.G101W, p.V126D, and p.A148T in the CDKN2A (HGNC ID: 1787) gene have been associated with the development of melanoma in different populations; however, this association has not been studied in Colombia. Methods. Cutaneous melanoma patients and healthy controls (85 cases and 166 controls) were included in this study. These subjects were screened through HRM-qPCR assay and detected variants in exon 1 and 2 of CDKN2A gene and confirmed with Sanger sequencing. Chi-square test was used to compare allele and genotype distributions between cases and controls. Odds ratio (OR) with 95% confidence interval (CI) was calculated to determine the association between polymorphisms and haplotypes with melanoma susceptibility. Statistical and haplotype analyses were performed using Stata® and R-Studio®. Results. Fifty-four percent of women were identified both in cases and controls. The frequencies of melanoma subtypes were 36,47% lentigo maligna, 24,71% acral lentiginous, 23,53% superficial extension, and 15,29% nodular. Variants in the CDKN2A gene were 11.76% in cases and 8.43% in controls. The most frequent was p.A148T in 5.88% of cases and in 4.82% of controls. GGTTG haplotype showed statistically significant differences between cases and controls (p value = 0.04). Conclusion. CDKN2A polymorphisms p.G101W, p.R24P, p.M53I, and A148T are not associated with melanoma susceptibility in the Colombian population; further studies regarding genetic interaction and additive effects between more variants are required.http://dx.doi.org/10.1155/2020/7458917
collection DOAJ
language English
format Article
sources DOAJ
author Jose D. Tovar-Parra
Luz D. Gutiérrez-Castañeda
Sebastián R. Gil-Quiñones
Jhon A. Nova
Leonardo Pulido
spellingShingle Jose D. Tovar-Parra
Luz D. Gutiérrez-Castañeda
Sebastián R. Gil-Quiñones
Jhon A. Nova
Leonardo Pulido
CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study
BioMed Research International
author_facet Jose D. Tovar-Parra
Luz D. Gutiérrez-Castañeda
Sebastián R. Gil-Quiñones
Jhon A. Nova
Leonardo Pulido
author_sort Jose D. Tovar-Parra
title CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study
title_short CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study
title_full CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study
title_fullStr CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study
title_full_unstemmed CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study
title_sort cdkn2a polymorphism in melanoma patients in colombian population: a case-control study
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2020-01-01
description Introduction. Melanoma is the most aggressive type of skin cancer, with poor prognosis in advanced stages. The incidence and mortality rates have increased in recent years. Single nucleotide polymorphisms p.R24P, p.M53I, p.G101W, p.V126D, and p.A148T in the CDKN2A (HGNC ID: 1787) gene have been associated with the development of melanoma in different populations; however, this association has not been studied in Colombia. Methods. Cutaneous melanoma patients and healthy controls (85 cases and 166 controls) were included in this study. These subjects were screened through HRM-qPCR assay and detected variants in exon 1 and 2 of CDKN2A gene and confirmed with Sanger sequencing. Chi-square test was used to compare allele and genotype distributions between cases and controls. Odds ratio (OR) with 95% confidence interval (CI) was calculated to determine the association between polymorphisms and haplotypes with melanoma susceptibility. Statistical and haplotype analyses were performed using Stata® and R-Studio®. Results. Fifty-four percent of women were identified both in cases and controls. The frequencies of melanoma subtypes were 36,47% lentigo maligna, 24,71% acral lentiginous, 23,53% superficial extension, and 15,29% nodular. Variants in the CDKN2A gene were 11.76% in cases and 8.43% in controls. The most frequent was p.A148T in 5.88% of cases and in 4.82% of controls. GGTTG haplotype showed statistically significant differences between cases and controls (p value = 0.04). Conclusion. CDKN2A polymorphisms p.G101W, p.R24P, p.M53I, and A148T are not associated with melanoma susceptibility in the Colombian population; further studies regarding genetic interaction and additive effects between more variants are required.
url http://dx.doi.org/10.1155/2020/7458917
work_keys_str_mv AT josedtovarparra cdkn2apolymorphisminmelanomapatientsincolombianpopulationacasecontrolstudy
AT luzdgutierrezcastaneda cdkn2apolymorphisminmelanomapatientsincolombianpopulationacasecontrolstudy
AT sebastianrgilquinones cdkn2apolymorphisminmelanomapatientsincolombianpopulationacasecontrolstudy
AT jhonanova cdkn2apolymorphisminmelanomapatientsincolombianpopulationacasecontrolstudy
AT leonardopulido cdkn2apolymorphisminmelanomapatientsincolombianpopulationacasecontrolstudy
_version_ 1715070005300690944